Sorry, but judging from this and your previous rants, you seem to hold a personal grudge against the CEO. However it may be, I'm certainly no apologist or in any way affiliated with the IMMD management or board.
Let's get the facts:
Revenue in 2015 came in at 1.22M, revenue for Q1/2016 is at least 1.2M as announced in the press release in March. In two months, IMMD generated the same revenue as in the last full year. Not much to complain about. That is a success, no matter what the further development in 2016 will be.
Q1 is in the books, any pre-release won't change any numbers whatsoever. IMMD guided for 10M revenue in 2016, let them work on it, Q1 can only be a small indicator, if they will be successful. Three months will not make a trend or determine the successful business plan execution either. IMMD may fail to live up to its projections in any single month in 2016. But so far I'm optimistic. If you are not, sell the stock, it's at a several month high right now.
Concerning dilution and warrants: As of March 30, 2016 there were 32,010,375 shares of common stock outstanding. IMMD is authorized to issue up to 50,000,000 shares of common stock. But IMMD is pursuing an uplisting to a senior exchange and that will not work out with exaggerated dilution. There have been equity fee and option payments for marketing purposes and there will be more based on certain milestones as published today. Would I like this to be more transparent? Yes. But I also see the need to raise some capital to finance a further expansion. And if that takes IMMD from 1.2M to 12M in revenues and to profitability in the established frames of 50M shares - so be it.
Let's see what happens and how IMMD can execute. Key projections to watch for:
- raw material sale in 2016: approx. 2M
- Skincare JV sales in 2016: 10M
- study on IMMD product as supplement in cancer therapy
- study on IMMD product in wound care / post-surgery application
- progress in pursuing an uplisting
AI
